Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronomic Capecitabine in High-Risk T1-2N1M0 Nasopharyngeal Carcinoma
NCT07248670Phase 3Active, not recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Oct 2025
- Primary completion
- Dec 2031
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of capecitabine in nasopharyngeal carcinoma (NPC), sponsored by Chongqing University Cancer Hospital. Started Oct 2025; status: active, not recruiting.
02
Drugs
capecitabine
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT07248670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07248670.